Results 211 to 220 of about 86,485 (257)

Tocilizumab but not Siltuximab prevents systemic inflammation in a humanized mouse model. [PDF]

Front Immunol
Zhang L, Wax J, Goldmann T, Mehrpouyan A, Müller A, Petersen F, Riemekasten G, Yu X.   +7 more
europepmc   +1 more source

Langerhans Cell Histiocytosis in Adults: A Canadian Multicenter Case Series

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Langerhans cell histiocytosis (LCH) is a rare clonal myeloid neoplasm. Canadian data on clinical characteristics, molecular profile, and treatment outcomes is limited. This study aims to report the initial experience of a Canadian rare diseases program, reflecting “real‐world” diagnostic pathways, referral patterns, and treatment heterogeneity
Stephanie Quon, Yaswanta Gummadi, Ibrahim Elsharawi, Jessica Dobson, Mariam Goubran, Ryan J. Stubbins, Eli L. Diamond, Luke Y. C. Chen   +7 more
wiley   +1 more source

Persistence, switching, and discontinuation patterns of b/tsDMARDs in patients with rheumatoid arthritis: a single-center retrospective cohort study from Saudi Arabia. [PDF]

Front Med (Lausanne)
Aldosari SA, Alkhaleel A, Alomar M, Alghalawin L, Alamer A.   +4 more
europepmc   +1 more source

Cytokine‐Driven Hyperinflammation in Long COVID: Mechanisms, Biomarkers, Complement Dysregulation, and Emerging Immunotherapies—A Narrative Review

Health Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims Long COVID, also known as post‐acute sequelae of SARS‐CoV‐2 infection (PASC), is a multisystem condition characterized by persistent symptoms that continue beyond the acute phase of infection. Growing evidence indicates that sustained immune dysregulation involving cytokine‐mediated inflammation, complement activation ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Add-on tocilizumab versus placebo for resistant major depression in psychiatric outpatients with low-grade inflammation in a tertiary public hospital in Southern Brazil: randomised triple-blind clinical trial protocol. [PDF]

BMJ Open
Portal PHG, Peixoto GN, de Matos MR, da Silva LCN, Alexandrino GB, Dutra PHG, Carniel BP, da Rocha NS.   +7 more
europepmc   +1 more source

A Case of Cytokine Release Syndrome (CRS) Related to Treatment With Lenvatinib Plus Pembrolizumab for Metastatic Clear Cell Renal Cell Carcinoma

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Cytokine release syndrome (CRS) is a systemic inflammatory response triggered by various factors, including infection and immunotherapy. Due to its nonspecific presentation, distinguishing CRS from other life‐threatening conditions remains challenging.
Kei Nagase, Hiroaki Kakinoki, Kazuki Nakamura, Yukako Yamaguchi, Shuhei Kusano, Yuka Kakinoki, Maki Kawasaki, Kazuma Udo, Shohei Tobu, Mitsuru Noguchi   +9 more
wiley   +1 more source

Checkpoint inhibitors create rogue regulatory T cells. [PDF]

J Clin Invest
Parashar S, Ley K.
europepmc   +1 more source

Longitudinal 1H and 129Xe Lung MRI in Patients With Post‐COVID Residual Lung Abnormalities

Journal of Magnetic Resonance Imaging, Volume 64, Issue 3, Page 669-682, September 2026.
ABSTRACT Background It is unclear how lung function may recover in patients with residual lung abnormalities (RLAs) following COVID‐19 pneumonia. Purpose To evaluate lung function trends over time in patients with RLAs following hospitalization due to COVID‐19. Study Type Prospective, multicenter longitudinal cohort study.
Laura C. Saunders, Guilhem J. Collier, Laurie J. Smith, Ho‐Fung Chan, Paul J. C. Hughes, Scarlett Strickland, Lotta Gustafsson, Thomas Newman, Megan Plowright, Zoë Gabriel, Lily M. Pearce, James T. Grist, Kher Lik Ng, Arthur Harrison, Charlotte E. Bolton, Jody Bray, Helen Marshall, Graham Norquay, Alberto M. Biancardi, Jimmy E. Ball, Neil J. Stewart, Kevin M. Johnson, Andrew J. Swift, Smitha Rajaram, John Blaikley, Stefan Stanel, Paul J. Collini, Gary H. Mills, Rod Lawson, Jonathan Brooke, Amanda T. Goodwin, Iain D. Stewart, Ling‐Pei Ho, Joseph Jacob, Thomas Meersmann, Galina E. Pavlovskaya, Fergus Gleeson, Ian P. Hall, Gisli Jenkins, Jim M. Wild, A. A. Roger Thompson, on behalf of the UK‐ILD consortium   +41 more
wiley   +1 more source

Interleukin-6 in complications of prematurity: from biomarker to targeted therapy. [PDF]

Front Pediatr
Xiao S, Zheng Q, Wang L, Wang Z, Bi G, Yang J.   +5 more
europepmc   +1 more source

Infection risk in rheumatoid arthritis patients treated with biologic and targeted therapies

Rheumatology &Autoimmunity, Volume 6, Issue 3, Page 149-159, September 2026.
In this context, infections associated with each biologic and targeted drug are summarized to inform the stratification of RA patients, including the characteristics of the susceptible patients and their concomitant therapy. We aim to provide a benefit‐risk analysis for clinical decision, and vital indications for the prevention of highly correlated ...
Lujing Wang, Jieshi Lin, Jie Qian
wiley   +1 more source